Abstract
OBJECTIVE: To evaluate laboratory safety monitoring in patients taking selected chronic prescription drugs.
DESIGN: Retrospective study using 1999–2001 claims data to calculate rates of missed laboratory tests (potential laboratory monitoring errors). Eleven drugs/drug groups and 64 laboratory tests were evaluated.
SETTING: Two staff/network model health maintenance organizations.
PATIENTS: Continuously enrolled health plan members age≥19 years taking ≥1 chronic medications.
MEASUREMENTS AND MAIN RESULTS: Among patients taking chronic medications (N=29,823 in 1999, N=32,423 in 2000, and N=36,811 in 2001), 47.1% in 1999, 45.0% in 2000, and 44.0% in 2001 did not receive ≥1 test recommended for safety monitoring. Taking into account that patients were sometimes missing more than 1 test for a given drug and that patients were frequently taking multiple drugs, the rate of all potential laboratory monitoring errors was 849/1,000 patients/year in 1999, 810/1,000 patients/year in 2000, and 797/1,000 patients/year in 2001. Rates of potential laboratory monitoring errors varied considerably across individual drugs and laboratory tests.
CONCLUSIONS: Lapses in laboratory monitoring of patients taking selected chronic medications were common. Further research is needed to determine whether, and to what extent, this failure to monitor patients is associated with adverse clinical outcomes.
This is a preview of subscription content, log in via an institution to check access.
References
Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556–64.
Gandhi TK, Burstin HR, Cook EF, et al. Drug complications in outpatients. J Gen Intern Med. 2000;15:149–54.
Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997;45:945–8.
Lazarou J, Pomeranz BH, Corey PH. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc. 1998;279:1200–5.
Schiff GD, Aggarwal HC, Kumar S, McNutt RA. Prescribing potassium despite hyperkalemia: medication errors uncovered by linking laboratory and pharmacy information systems. Am J Med. 2000;109:494–7.
Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. J Am Med Assoc. 2001;286:831–3.
Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. J Am Med Assoc. 2003;298:1107–16.
Gurwitz JH, Field TS, Avorn J, Bates DW. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109:87–94.
Physician’s Desk Reference. 54th ed. Oradell, NJ: Medical Economics; 2000.
Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity. Arch Intern Med. 200;163:688–92.
Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Eng J Med. 2004;351:526–8.
Wrenger E, Muller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. Br Med J. 2003;327:147–9.
Wyllie E, Wyllie R. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy. Epilepsia. 1991;32(suppl 5):S74-S79.
Author information
Authors and Affiliations
Corresponding author
Additional information
Funding for this study was provided by the U.S. Agency for Healthcare Research and Quality, task order 290-00-0015-04.
Rights and permissions
About this article
Cite this article
Hurley, J.S., Roberts, M., Solberg, L.I. et al. Brief report: Laboratory safety monitoring of chronic medications in ambulatory care settings. J GEN INTERN MED 20, 331–333 (2005). https://doi.org/10.1111/j.1525-1497.2005.40182.x
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1525-1497.2005.40182.x